Loading
A phase 1/2 trial of Cemiplimab in prostate cancer and renal cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07594106 by Regeneron Pharmaceuticals, with 265 participants planned, started 2026-07-20 and due to reach its primary completion in 2030-10-27. Interventions recorded: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, Cemiplimab, Metastatic castration-resistant prostate cancer, Renal cell carcinoma.
Shares Regeneron, Cemiplimab, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/